Stereotaxis, Inc.

STXS

$1.38

+0.73%

2026-09-02 16:00:00 EDT+$0.01

Healthcare

Medical - Instruments & Supplies

AMEX

Active Trading

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment ...

Price Action of STXS

$1.38

+0.73%+$0.01

High—

Low—

52W High-61.6%

Rel. vol—

Interval

Range5.3h

Volume—SMA5SMA10

—

Stereotaxis, Inc. specializes in robotic magnetic navigation systems used in interventional cardiology and electrophysiology. Its key products include the Genesis RMN System, the Odyssey Solution, and related devices, including the Stereotaxis Imaging Model S x-ray system. The company aims to enhance the precision and safety of procedures for treating arrhythmias ...Stereotaxis, Inc. specializes in robotic magnetic navigation systems used in interventional cardiology and electrophysiology. Its key products include the Genesis RMN System, the Odyssey Solution, and related devices, including the Stereotaxis Imaging Model S x-ray system. The company aims to enhance the precision and safety of procedures for treating arrhythmias and coronary artery disease. With a focus on innovation, Stereotaxis has developed technologies like the Synchrony system, which received FDA clearance and is expected to generate significant revenue. The company has plans to expand into markets such as China with second-generation robots. Financially, Stereotaxis has a market capitalization of approximately $141 million, with revenue per share of $0.315 and a gross profit margin of 53.9%. However, the company is currently operating at a loss, with a net profit margin of -69.5% and negative operating cash flow. It invests heavily in R&D (30.2% of revenue) and sales & administration (96.3% of revenue). The company has a CFO and a workforce of 131 employees. Under the leadership of CEO David L. Fischel, who has served since 2017, Stereotaxis aims to restore financial health and drive commercial growth with a focus on advancing robotics in interventional medicine.ExpandCollapse

Founded

1990

Employees

131

CEO

David L. Fischel

Full Name

Stereotaxis, Inc.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

ROE

-132.62%

Market Cap

$0.14B

Current Ratio

1.42

WACC

10.87%

ROIC

-78.46%

Contact Information

https://www.stereotaxis.com

314 678 6100

710 North Tucker Boulevard, St. Louis, MO 63101

Key Metrics of STXS

Snapshot

Latest / TTM · 6 periods

Market Cap

$135.15M

ROCE

-76.3%

EV / EBITDA

-6.19x

-2.3% YoY

FCF Yield

-11.4%

-4.8% YoY

Cash Conversion Cycle

322.8d

Current Ratio

1.42

Quick take

TTM —

Positive CCC

Financial Highlights of STXS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

55.6%

Net Margin

-74.2%

P/E Ratio

-5.63x

n/a

Debt / Equity

0.30

n/a

Current Ratio

1.42

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of STXS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.05 · Revenue $9.60M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.04 · Revenue $10.73M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.21 · Revenue $34.33M · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.04 · Revenue $10.50M · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.05 · Revenue $7.67M
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.06 · Revenue $6.29M
View filing
Mar 12, 2026
FY2025 · Annual results
EPS $-0.25 · Revenue $32.38M
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.07 · Revenue $7.46M
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.05 · Revenue $8.80M
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.07 · Revenue $7.47M
View filing

Financial Statements of STXS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$32.4M	+20.3%	+21.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-21.6M	+10.0%	+23.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+52.7%	-2.7%	-3.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-68.3%	+25.7%	+27.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-66.8%	+25.2%	+37.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-13.8M	-61.5%	-6.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-42.6%	-34.3%	+12.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	29.0%	-44.7%	+9.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.51x	+23.7%	-8.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$52.3M	+11.8%	+2.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.25 vs -0.24	-2.3%	-0.05 vs -0.05	0.0%
Revenue Surprise	$32.4M vs $32.8M	-1.2%	$7.7M vs $8.3M	-8.1%

Insider Transactions of STXS

Acquisitions (A)

Since Jan 2, 2026

Disposals (D)

Since Jan 2, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 1, 2026	SHAMIR NACHUM	director	Common Stock	A	43,103	—
Jul 1, 2026	Benfer David	director	Common Stock	A	43,103	—
Jul 1, 2026	Levin Ross B	director	Common Stock	A	43,103	—
Jul 1, 2026	Curet Myriam	director	Common Stock	A	43,103	—
Jul 1, 2026	Fischel Nathan	director, 10 percent owner:	Common Stock	A	43,103	—

Earnings Call Transcript of STXS

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good afternoon. Thank you for joining us for Stereotaxis' Second Quarter 2026 Earnings Conference Call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute towards forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update this statement. [Operator Instructions] As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis. Please go ahead. David Fischel: Thank you, operator, and good afternoon, everyone. On our last call, we discussed in detail the structural transformations taking place at Stereotaxis. We just celebrated a particularly milestone-rich period with regulatory approvals for a new robot, both therapeutic and diagnostic catheters, and a digital surgery system. These products individually and collectively as a synergistic ecosystem create an attractive foundation for us to scale commercialization with reduced barriers to adoption and a much more attractive business model. During the second quarter, Stereotaxis reached an important commercial inflection point as our expanded product offering is now generating accelerating adoption. It is still just the initial green shoots of commercial success, but the early experience and feedback provides confidence in sustained progress. I'll discuss on today's call the primary areas of commercial progress, the feedback from the field, and our efforts to accelerate growth. I'll then share some additional updates on the robust pipeline of innovations that we continue to advance and that will drive a second wave of growth over the coming years. Kim will then share financial details for the quarter and we'll open the line for questions. A key area of focus in the second quarter was on the launch of MAGiC in the U.S. following FDA approval in the first quarter. While supply constrained and still just in the early adoption phase, that launch allows us to reach a multi-year high point in recurring revenue, which surpassed $6 million in the quarter, driven by over $1 million in robotic catheter revenue. Our robotic catheter revenue is scaling significantly in both the U.S. and Europe with nearly 300% sequential growth from the first to the second quarter. We are in the early phase of adoption of MAGiC, with about a dozen U.S. sites receiving hospital approval to purchase the catheter and beginning procedures in …

Leadership Team of STXS

4 executives

Name	Title	Compensation	Gender	Year Born	Status
Kimberly R. Peery	Chief Financial Officer	USD 270,711	Female	1969	Active
David Leo Fischel	Chief Executive Officer & Chairman	USD 64,390	—	1987	Active
Keith Galloway	Vice President of Operations	—	Male	—	Active
Patricia S. Williams	General Counsel & Secretary	—	Female	1967	Active

Recent News of STXS

Seeking Alpha8/11/2026Neutral

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

MarketBeat8/11/2026Neutral

Stereotaxis Q2 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.

Zacks Investment Research8/11/2026Neutral

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.

GlobeNewsWire8/11/2026Neutral

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.

GlobeNewsWire7/21/2026Neutral

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.

Historical Employee Count of STXS

Current

131

Change

-5.76%

Minimum

122

Maximum

139

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	131	10-K	Mar 12, 2026	View
Dec 31, 2024	139	10-K	Mar 14, 2025	View
Dec 31, 2023	122	10-K	Mar 8, 2024	View
Dec 31, 2022	130	10-K	Mar 9, 2023	View
Dec 31, 2021	130	10-K	Mar 10, 2022	View

Related stocksMedical - Equipment & Services

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Stereotaxis, Inc.